PAHC — PHIBRO ANIMAL HEALTH CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1069899 ·
Last close
$35.31
Market Cap
$743.94M
52W High
$37.92
52W Low
$28.13
ADV30
196,013
Next earnings
2026-08-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 383,543,000 | 125,675,000 | 44,653,000 | 24,024,000 | 1,445,118,000 | 54,929,000 | 1,083,291,000 |
| Dec 2025 | 373,910,000 | 132,656,000 | 50,326,000 | 27,459,000 | 1,405,553,000 | 55,486,000 | 1,073,192,000 |
| Sep 2025 | 363,893,000 | 119,783,000 | 51,260,000 | 26,527,000 | 1,385,524,000 | 72,769,000 | 1,073,843,000 |
| Jun 2025 | 378,697,000 | 110,009,000 | 33,718,000 | 17,224,000 | 1,360,900,000 | 68,039,000 | 1,075,218,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$66,132,000
Investing CF
$-62,038,000
Financing CF
$-12,711,000
CapEx
$-53,361,000
Dividends Paid
$-19,460,000
Buybacks
—
EPS Diluted TTM
$2.33
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$336,115,000
Inventory
$539,699,000
Receivables
$221,546,000
ST Investments
$22,522,000
EBIT TTM
$171,232,000
Pretax Income TTM
$128,852,000
Interest Exp TTM
$42,380,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,500,043,008
EBITDA
$234,754,000
Free Cash Flow
$-17,678,250
Enterprise Value
$2,183,851,520
Total Cash
$78,138,000
Total Debt
$788,678,976
Shares Out
21,068,682
Trailing EPS
$2.33
Book Value
$8.92
ROE
30.3%
ROA
8.4%
Div Yield
1.32%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,296,215,000 | 110,465,000 | 48,264,000 | 1,360,900,000 | 1,075,218,000 | — | 80,124,000 |
| Jun 2024 | 1,017,679,000 | 53,315,000 | 2,416,000 | 982,184,000 | 725,543,000 | — | 87,594,000 |
| Jun 2023 | 977,889,000 | 71,847,000 | 32,606,000 | 971,397,000 | 688,888,000 | — | 13,310,000 |
| Jun 2022 | 942,261,000 | 78,986,000 | 49,175,000 | 931,699,000 | 669,257,000 | — | 31,649,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.34
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $35.31 · call volume: 43 · put volume: 63
Expected Move to 2026-09-18:
±$7.95
(22.51%) —
implied range
$27.36 –
$43.26
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNPR | Monopar Therapeutics | $747.47M | $111.36 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $732.79M | $9.14 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $755.77M | $77.03 | — |
| OCS | Oculis Holding AG | $731.86M | $13.18 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $718.32M | $35.28 | — |
News headlines (Yahoo Finance, 1h cache)
Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
2026-08-21 13:15 · Yahoo
Is Phibro Animal Health (PAHC) Still Reasonable After A 149% Run?
2026-08-20 19:09 · Yahoo
Phibro Animal Health (PAHC) Could Be 22% Undervalued On Upcoming Earnings
2026-08-20 16:15 · Yahoo
2 Small-Cap Stocks with Solid Fundamentals and 1 We Avoid
2026-08-18 12:37 · Yahoo
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
2026-08-19 20:30 · Yahoo
Should You Continue to Retain PAHC Stock in Your Portfolio?
2026-08-19 13:54 · Yahoo
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
2026-08-10 17:29 · Yahoo
Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline
2026-08-10 17:27 · Yahoo
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up
2026-08-07 17:57 · Yahoo
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
2026-08-07 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.